Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics is a research paper published in Science Translational Medicine (2020). On theSindex it has a DataRank of 0.718. It has been cited 119 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.718
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Wellcome Trust
Grant: 086596
Wellcome Trust
Grant: 088158
Wellcome Trust
Grant: 088158/Z/09/Z
Wellcome Trust
Grant: 104085
Wellcome Trust
Grant: 202922
Wellcome Trust
Grant: 202922/Z/16/Z
Medical Research Council
Grant: MC_PC_13049
Medical Research Council
Grant: MC_PC_14135
British Heart Foundation
Grant: FS/18/23/33512
Medical Research Council
Grant: MC_UU_00011/1
Medical Research Council
Grant: MC_UU_12026/2
British Heart Foundation
Grant: RE/13/1/30181
Medical Research Council
Grant: MC_UU_00017/1
Medical Research Council
Grant: MC_U137686851
NICHD NIH HHS
Grant: P50 HD028138
Wellcome Trust
Grant: 104085/Z/14/Z
Dutch Research Council (NWO)
National Institutes of Health
Wellcome Trust
British Heart Foundation
Estonian Research Council
NIHR Oxford Biomedical Research Centre
Li Ka Shing Foundation
John Fell Fund, University of Oxford
Medical Research Council
FWCI
5.86
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals